A Phase 1 interventional study of ASC-01 and Aripiprazole and sertraline in Healthy Male Adults, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-03.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two sertraline 50-mg tablets (Cohort 1).
To investigate food effect on plasma pharmacokinetics of aripiprazole and sertraline by single oral administration of ASC-01 under a fasting or fed condition (Cohort 2).
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting. At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.
Drug: ASC-01 · Drug: Aripiprazole and sertraline
At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting. At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.
Drug: ASC-01 · Drug: Aripiprazole and sertraline
At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting. At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.
Drug: ASC-01 · Drug: Aripiprazole and sertraline
At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast. At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.
Drug: ASC-01 · Drug: Aripiprazole and sertraline
Aripiprazole 3 mg/sertraline 100 mg combination drug
Drug pages: Aripiprazole · Sertraline
Aripiprazole 3 mg and sertraline 100 mg
Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1
Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1
Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
Cmax of Aripiprazole and Sertraline in Cohort 2
Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
AUC168h of Aripiprazole and Sertraline in Cohort 2
Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
| Milestone | Cohort 1: ASC-01 First | Cohort 1: Aripiprazole/Sertraline Concomitant First | Cohort 2: ASC-01 Under Fasted First | Cohort 2: ASC-01 Under Fed First |
|---|---|---|---|---|
| Started | 27 | 27 | 10 | 10 |
| Completed | 25 | 25 | 10 | 10 |
| Not completed | 2 | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| ng/mL | ASC-01 | Aripiprazole/Sertraline Concomitant |
|---|---|---|
| Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1 | 18.8 ± 5.33 | 16.9 ± 4.38 |
| ng*h/mL | ASC-01 | Aripiprazole/Sertraline Concomitant |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1 | 783 ± 273 | 779 ± 236 |
| ng/mL | ASC-01 Under Fasted | ASC-01 Under Fed |
|---|---|---|
| Aripiprazole | 16.9 ± 5.23 | 16.6 ± 3.74 |
| Sertraline | 28.9 ± 10.7 | 36.5 ± 15.6 |
| ng*h/mL | ASC-01 Under Fasted | ASC-01 Under Fed |
|---|---|---|
| Aripiprazole | 701 ± 221 | 865 ± 219 |
| Sertraline | 904 ± 415 | 1060 ± 468 |
Collected over Treatment-emergent adverse events occurring up to 8 days after dosing date were collected.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - ASC-01 | 0/52 (0%) | 0/52 (0%) | 44/52 (84.6%) |
| Cohort 1 - Aripiprazole/Sertraline Concomitant | 0/52 (0%) | 0/52 (0%) | 43/52 (82.7%) |
| Cohort 2 - ASC-01 Under Fasted | 0/20 (0%) | 0/20 (0%) | 12/20 (60%) |
| Cohort 2 - ASC-01 Under Fed | 0/20 (0%) | 0/20 (0%) | 14/20 (70%) |
| Event | Cohort 1 - ASC-01 | Cohort 1 - Aripiprazole/Sertraline Concomitant | Cohort 2 - ASC-01 Under Fasted | Cohort 2 - ASC-01 Under Fed |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 39/52 | 38/52 | 11/20 | 10/20 |
| VomitingGastrointestinal disorders | 20/52 | 17/52 | 6/20 | 9/20 |
| DiarrhoeaGastrointestinal disorders | 7/52 | 9/52 | 3/20 | 1/20 |
| Dizziness posturalNervous system disorders | 0/52 | 1/52 | 0/20 | 2/20 |
| Decreased appetiteMetabolism and nutrition disorders | 4/52 | 3/52 | 1/20 | 1/20 |
| TachycardiaCardiac disorders | 3/52 | 2/52 | 0/20 | 0/20 |
| NasopharyngitisInfections and infestations | 0/52 | 0/52 | 0/20 | 1/20 |
| Orthostatic hypotensionVascular disorders | 0/52 | 0/52 | 0/20 | 1/20 |
| PharyngitisInfections and infestations | 0/52 | 1/52 | 0/20 | 0/20 |
| Blood creatine phosphokinase increasedInvestigations | 1/52 | 1/52 | 0/20 | 0/20 |
Safety Set: subjects who received investigational medicinal product (IMP) at least once.
| Age, Categorical(Participants) | Cohort 1: ASC-01 First | Cohort 1: Aripiprazole/Sertraline Concomitant First | Cohort 2: ASC-01 Under Fasted First | Cohort 2: ASC-01 Under Fed First | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 27 | 27 | 10 | 10 | 74 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1: ASC-01 First | Cohort 1: Aripiprazole/Sertraline Concomitant First | Cohort 2: ASC-01 Under Fasted First | Cohort 2: ASC-01 Under Fed First | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 27 | 27 | 10 | 10 | 74 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: ASC-01 First | Cohort 1: Aripiprazole/Sertraline Concomitant First | Cohort 2: ASC-01 Under Fasted First | Cohort 2: ASC-01 Under Fed First | Total |
|---|---|---|---|---|---|
| Japanese | 27 | 27 | 10 | 10 | 74 |
| Region of Enrollment(Participants) | Cohort 1: ASC-01 First | Cohort 1: Aripiprazole/Sertraline Concomitant First | Cohort 2: ASC-01 Under Fasted First | Cohort 2: ASC-01 Under Fed First | Total |
|---|---|---|---|---|---|
| Japan | 27 | 27 | 10 | 10 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Jan 2018, 1 month.
Results were first posted in May 2021, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Co., Ltd. →